FibroGen to Report Third Quarter 2022 Financial Results

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) will release its third quarter 2022 financial results on November 7, 2022, after market close. The company will also host a conference call with investors at 5:00 p.m. ET to discuss its corporate and financial performance. FibroGen focuses on developing innovative therapeutics, including the anti-CTGF monoclonal antibody, Pamrevlumab, and the anemia treatment, Roxadustat, which is already approved in several countries. The company is expanding its research into immuno-oncology and autoimmune therapies.

Positive

• FibroGen's Roxadustat is already approved in multiple countries, indicating market confidence.
• Expansion into immuno-oncology and autoimmune therapies may drive future growth.

Negative

• None.

SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link (webcast replay).

About FibroGen  
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer, and Duchenne muscular dystrophy (DMD). Roxadustat (爱瑞卓^®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and patients not on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe for anemia associated with myelodysplastic syndromes (MDS), and in Phase 3 clinical development in China for treatment of chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com. 

Contacts: FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.978.1434
mtung@fibrogen.com

Media:
Meichiel Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com

FAQ

When will FibroGen announce its third quarter 2022 financial results?

FibroGen will announce its third quarter 2022 financial results on November 7, 2022, after market close.

What time is the conference call for FibroGen's Q3 results?

The conference call to discuss FibroGen's Q3 results is scheduled for 5:00 p.m. ET on November 7, 2022.

How can I access the FibroGen conference call?

You can access the FibroGen conference call via the Investor Relations page on their website or by phone using the provided registration link.

What is the primary focus of FibroGen's business?

FibroGen focuses on discovering, developing, and commercializing therapeutics, particularly in the fields of connective tissue growth factor and hypoxia-inducible factor.

What is Pamrevlumab and its current status?

Pamrevlumab is an anti-CTGF human monoclonal antibody in clinical development for several serious conditions, including idiopathic pulmonary fibrosis.